Unlocking the potential of bispecific antibody-drug conjugates for targeted cancer therapy
Antibody-drug conjugates (ADCs) have emerged as a promising approach in cancer therapy, offering a 'magic bullet' strategy that combines the precision of monoclonal antibodies with the potency of cytotoxic drugs.
Oct 23, 2024
0
20
